{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T12:10:28Z","timestamp":1786450228916,"version":"build-2736575974"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s00277-024-05968-6","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T07:05:36Z","timestamp":1725519936000},"page":"867-879","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical characteristics and management of paroxysmal nocturnal haemoglobinuria in Latin America: a narrative review"],"prefix":"10.1007","volume":"104","author":[{"given":"Valentina","family":"Goldschmidt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elia Ixel","family":"Apodaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenny Mauricio","family":"G\u00e1lvez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Wannesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Scheinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,5]]},"reference":[{"issue":"18","key":"5968_CR1","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1182\/blood-2014-02-522128","volume":"124","author":"RA Brodsky","year":"2014","unstructured":"Brodsky RA (2014) Paroxysmal nocturnal hemoglobinuria. Blood 124(18):2804\u20132811. https:\/\/doi.org\/10.1182\/blood-2014-02-522128","journal-title":"Blood"},{"key":"5968_CR2","doi-asserted-by":"publisher","first-page":"17028","DOI":"10.1038\/nrdp.2017.28","volume":"3","author":"A Hill","year":"2017","unstructured":"Hill A, DeZern AE, Kinoshita T, Brodsky RA (2017) Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers 3:17028. https:\/\/doi.org\/10.1038\/nrdp.2017.28","journal-title":"Nat Rev Dis Primers"},{"key":"5968_CR3","unstructured":"Shah N, Bhatt H (2023) Paroxysmal nocturnal hemoglobinuria. [Updated 2022 Aug 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK562292\/. Accessed 19 June 2024"},{"issue":"1","key":"5968_CR4","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/imr.13137","volume":"313","author":"AM Risitano","year":"2023","unstructured":"Risitano AM, Frieri C, Urciuoli E, Marano L (2023) The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: From a pathogenic mechanism to a therapeutic target. Immunol Rev 313(1):262\u2013278. https:\/\/doi.org\/10.1111\/imr.13137","journal-title":"Immunol Rev"},{"key":"5968_CR5","doi-asserted-by":"publisher","first-page":"204062072210910","DOI":"10.1177\/20406207221091046","volume":"13","author":"AG Kulasekararaj","year":"2022","unstructured":"Kulasekararaj AG, Brodsky RA, Nishimura JI, Patriquin CJ, Schrezenmeier H (2022) The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria. Ther Adv Hematol 13:20406207221091050. https:\/\/doi.org\/10.1177\/20406207221091046","journal-title":"Ther Adv Hematol"},{"issue":"6","key":"5968_CR6","doi-asserted-by":"publisher","first-page":"16271","DOI":"10.20452\/pamw.16271","volume":"132","author":"U Szlendak","year":"2022","unstructured":"Szlendak U, Budziszewska B, Spychalska J, Drozd-Soko\u0142owska J, Patkowska E, Nowak J (2022) Paroxysmal nocturnal hemoglobinuria: advances in the understanding of pathophysiology, diagnosis, and treatment. Pol Arch Intern Med 132(6):16271. https:\/\/doi.org\/10.20452\/pamw.16271","journal-title":"Pol Arch Intern Med"},{"issue":"1","key":"5968_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ejh.13059","volume":"101","author":"A R\u00f6th","year":"2018","unstructured":"R\u00f6th A, Maciejewski J, Nishimura JI, Jain D, Weitz JI (2018) Screening and diagnostic clinical algorithm for paroxysmal nocturnal hemoglobinuria: Expert consensus. Eur J Haematol 101(1):3\u201311. https:\/\/doi.org\/10.1111\/ejh.13059","journal-title":"Eur J Haematol"},{"issue":"7","key":"5968_CR8","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1007\/s00277-020-04052-z","volume":"99","author":"H Schrezenmeier","year":"2020","unstructured":"Schrezenmeier H, R\u00f6th A, Araten DJ, Kanakura Y, Larratt L, Shammo JM, Wilson A, Shayan G, Maciejewski JP (2020) Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry. Ann Hematol 99(7):1505\u20131514. https:\/\/doi.org\/10.1007\/s00277-020-04052-z","journal-title":"Ann Hematol"},{"issue":"4","key":"5968_CR9","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s12288-016-0654-2","volume":"32","author":"AA Mohammed","year":"2016","unstructured":"Mohammed AA, El-Tanni H, Atiah TA, Atiah AA, Atiah MA, Rasmy AA (2016) Paroxysmal nocturnal hemoglobinuria: from bench to bed. Indian J Hematol Blood Transfus 32(4):383\u2013391. https:\/\/doi.org\/10.1007\/s12288-016-0654-2","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"3","key":"5968_CR10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1177\/2040620716681748","volume":"8","author":"M Griffin","year":"2017","unstructured":"Griffin M, Munir T (2017) Management of thrombosis in paroxysmal nocturnal hemoglobinuria: a clinician\u2019s guide. Ther Adv Hematol 8(3):119\u2013126. https:\/\/doi.org\/10.1177\/2040620716681748","journal-title":"Ther Adv Hematol"},{"issue":"12","key":"5968_CR11","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1182\/blood-2005-04-1717","volume":"106","author":"C Parker","year":"2005","unstructured":"Parker C, Omine M, Richards S, Nishimura J, Bessler M, Ware R, Hillmen P, Luzzatto L, Young N, Kinoshita T, Rosse W, Soci\u00e9 G, International PNH Interest Group (2005) Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 106(12):3699\u20133709. https:\/\/doi.org\/10.1182\/blood-2005-04-1717","journal-title":"Blood"},{"issue":"4","key":"5968_CR12","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/cyto.b.20525","volume":"78","author":"MJ Borowitz","year":"2010","unstructured":"Borowitz MJ, Craig FE, Digiuseppe JA, Illingworth AJ, Rosse W, Sutherland DR, Wittwer CT, Richards SJ, Clinical Cytometry Society (2010) Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytometry B Clin Cytom 78(4):211\u2013230. https:\/\/doi.org\/10.1002\/cyto.b.20525","journal-title":"Cytometry B Clin Cytom"},{"key":"5968_CR13","doi-asserted-by":"publisher","first-page":"7256","DOI":"10.12659\/MSM.910614","volume":"24","author":"G Peng","year":"2018","unstructured":"Peng G, Yang W, Jing L, Zhang L, Li Y, Ye L, Li Y, Li J, Fan H, Song L, Zhao X, Zhang F (2018) Iron deficiency in patients with paroxysmal nocturnal hemoglobinuria: a cross-sectional survey from a single institution in China. Med Sci Monit 24:7256\u20137263. https:\/\/doi.org\/10.12659\/MSM.910614","journal-title":"Med Sci Monit"},{"issue":"Suppl 1","key":"5968_CR14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/ijlh.13011","volume":"41","author":"AJ Illingworth","year":"2019","unstructured":"Illingworth AJ, Marinov I, Sutherland DR (2019) Sensitive and accurate identification of PNH clones based on ICCS\/ESCCA PNH Consensus Guidelines-A summary. Int J Lab Hematol 41(Suppl 1):73\u201381. https:\/\/doi.org\/10.1111\/ijlh.13011","journal-title":"Int J Lab Hematol"},{"issue":"12","key":"5968_CR15","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMoa061648","volume":"355","author":"P Hillmen","year":"2006","unstructured":"Hillmen P, Young NS, Schubert J, Brodsky RA, Soci\u00e9 G, Muus P, R\u00f6th A, Szer J, Elebute MO, Nakamura R, Browne P, Risitano AM, Hill A, Schrezenmeier H, Fu CL, Maciejewski J, Rollins SA, Mojcik CF, Rother RP, Luzzatto L (2006) The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 355(12):1233\u20131243. https:\/\/doi.org\/10.1056\/NEJMoa061648","journal-title":"N Engl J Med"},{"issue":"12","key":"5968_CR16","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.1182\/blood-2007-06-095646","volume":"110","author":"P Hillmen","year":"2007","unstructured":"Hillmen P, Muus P, D\u00fchrsen U, Risitano AM, Schubert J, Luzzatto L, Schrezenmeier H, Szer J, Brodsky RA, Hill A, Soci\u00e9 G, Bessler M, Rollins SA, Bell L, Rother RP, Young NS (2007) Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 110(12):4123\u20134128. https:\/\/doi.org\/10.1182\/blood-2007-06-095646","journal-title":"Blood"},{"issue":"4","key":"5968_CR17","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","volume":"111","author":"RA Brodsky","year":"2008","unstructured":"Brodsky RA, Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Schubert J, Gaya A, Coyle L, de Castro C, Fu CL, Maciejewski JP, Bessler M, Kroon HA, Rother RP, Hillmen P (2008) Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 111(4):1840\u20131847. https:\/\/doi.org\/10.1182\/blood-2007-06-094136","journal-title":"Blood"},{"issue":"8","key":"5968_CR18","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/ajh.21757.Erratum.In:AmJHematol.2010;85(11):911","volume":"85","author":"P Hillmen","year":"2010","unstructured":"Hillmen P, Elebute M, Kelly R, Urbano-Ispizua A, Hill A, Rother RP, Khursigara G, Fu CL, Omine M, Browne P, Rosse W (2010) Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol 85(8):553\u2013559. https:\/\/doi.org\/10.1002\/ajh.21757.Erratum.In:AmJHematol.2010;85(11):911","journal-title":"Am J Hematol"},{"issue":"25","key":"5968_CR19","doi-asserted-by":"publisher","first-page":"6786","DOI":"10.1182\/blood-2011-02-333997","volume":"117","author":"RJ Kelly","year":"2011","unstructured":"Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M, Mitchell LD, Cohen DR, Gregory WM, Hillmen P (2011) Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood 117(25):6786\u20136792. https:\/\/doi.org\/10.1182\/blood-2011-02-333997","journal-title":"Blood"},{"issue":"1","key":"5968_CR20","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/bjh.12347","volume":"162","author":"P Hillmen","year":"2013","unstructured":"Hillmen P, Muus P, R\u00f6th A, Elebute MO, Risitano AM, Schrezenmeier H, Szer J, Browne P, Maciejewski JP, Schubert J, Urbano-Ispizua A, de Castro C, Soci\u00e9 G, Brodsky RA (2013) Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 162(1):62\u201373. https:\/\/doi.org\/10.1111\/bjh.12347","journal-title":"Br J Haematol"},{"issue":"3","key":"5968_CR21","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s40265-019-01068-2","volume":"79","author":"K McKeage","year":"2019","unstructured":"McKeage K (2019) Ravulizumab: first global approval. Drugs 79(3):347\u2013352. https:\/\/doi.org\/10.1007\/s40265-019-01068-2","journal-title":"Drugs"},{"key":"5968_CR22","doi-asserted-by":"publisher","first-page":"263300402095934","DOI":"10.1177\/2633004020959349","volume":"1","author":"M Griffin","year":"2020","unstructured":"Griffin M, Kelly R, Pike A (2020) A review of the treatment landscape in paroxysmal nocturnal haemoglobinuria: where are we now and where are we going? Ther Adv Rare Dis 1:2633004020959349. https:\/\/doi.org\/10.1177\/2633004020959349","journal-title":"Ther Adv Rare Dis"},{"issue":"6","key":"5968_CR23","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1182\/blood-2018-09-876136","volume":"133","author":"JW Lee","year":"2019","unstructured":"Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, Pessoa V, Gualandro S, F\u00fcreder W, Ptushkin V, Rottinghaus ST, Volles L, Shafner L, Aguzzi R, Pradhan R, Schrezenmeier H, Hill A (2019) Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood 133(6):530\u2013539. https:\/\/doi.org\/10.1182\/blood-2018-09-876136","journal-title":"Blood"},{"issue":"6","key":"5968_CR24","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1182\/blood-2018-09-876805","volume":"133","author":"AG Kulasekararaj","year":"2019","unstructured":"Kulasekararaj AG, Hill A, Rottinghaus ST, Langemeijer S, Wells R, Gonzalez-Fernandez FA, Gaya A, Lee JW, Gutierrez EO, Piatek CI, Szer J, Risitano A, Nakao S, Bachman E, Shafner L, Damokosh AI, Ortiz S, R\u00f6th A, Peffault de Latour R (2019) Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood 133(6):540\u2013549. https:\/\/doi.org\/10.1182\/blood-2018-09-876805","journal-title":"Blood"},{"issue":"3","key":"5968_CR25","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/14712598.2020.1725468","volume":"20","author":"JW Lee","year":"2020","unstructured":"Lee JW, Kulasekararaj AG (2020) Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Expert Opin Biol Ther 20(3):227\u2013237. https:\/\/doi.org\/10.1080\/14712598.2020.1725468","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"5968_CR26","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3324\/haematol.2019.236877","volume":"106","author":"RA Brodsky","year":"2021","unstructured":"Brodsky RA, Peffault de Latour R, Rottinghaus ST, R\u00f6th A, Risitano AM, Weitz IC, Hillmen P, Maciejewski JP, Szer J, Lee JW, Kulasekararaj AG, Volles L, Damokosh AI, Ortiz S, Shafner L, Liu P, Hill A, Schrezenmeier H (2021) Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria. Haematologica 106(1):230\u2013237. https:\/\/doi.org\/10.3324\/haematol.2019.236877","journal-title":"Haematologica"},{"issue":"12","key":"5968_CR27","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1182\/blood.2019003399","volume":"135","author":"A R\u00f6th","year":"2020","unstructured":"R\u00f6th A, Nishimura JI, Nagy Z, Ga\u00e0l-Weisinger J, Panse J, Yoon SS, Egyed M, Ichikawa S, Ito Y, Kim JS, Ninomiya H, Schrezenmeier H, Sica S, Usuki K, Sicre de Fontbrune F, Soret J, Sostelly A, Higginson J, Dieckmann A, Gentile B, Anzures-Cabrera J, Shinomiya K, Jordan G, Biedzka-Sarek M, Klughammer B, Jahreis A, Bucher C, Peffault de Latour R (2020) The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. Blood 135(12):912\u2013920. https:\/\/doi.org\/10.1182\/blood.2019003399","journal-title":"Blood"},{"issue":"9","key":"5968_CR28","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1002\/ajh.26998","volume":"98","author":"H Liu","year":"2023","unstructured":"Liu H, Xia L, Weng J, Zhang F, He C, Gao S, Jia J, Chang AC, Lundberg P, Shi J, Sima CS, Sostelly A, Sreckovic S, Xiao Z, Zhang Z, Fu R (2023) Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, phase 3, single-arm study. Am J Hematol 98(9):1407\u20131414. https:\/\/doi.org\/10.1002\/ajh.26998","journal-title":"Am J Hematol"},{"issue":"12","key":"5968_CR29","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1182\/bloodadvances.2019031591","volume":"3","author":"L Zhang","year":"2019","unstructured":"Zhang L, Dai Y, Huang P, Saunders TL, Fox DA, Xu J, Lin F (2019) Absence of complement component 3 does not prevent classical pathway-mediated hemolysis. Blood Adv 3(12):1808\u20131814. https:\/\/doi.org\/10.1182\/bloodadvances.2019031591","journal-title":"Blood Adv"},{"issue":"11","key":"5968_CR30","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1182\/bloodadvances.2022009129","volume":"7","author":"RSM Wong","year":"2023","unstructured":"Wong RSM, Navarro-Cabrera JR, Comia NS, Goh YT, Idrobo H, Kongkabpan D, G\u00f3mez-Almaguer D, Al-Adhami M, Ajayi T, Alvarenga P, Savage J, Deschatelets P, Francois C, Grossi F, Dumagay T (2023) Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria. Blood Adv 7(11):2468\u20132478. https:\/\/doi.org\/10.1182\/bloodadvances.2022009129","journal-title":"Blood Adv"},{"issue":"11","key":"5968_CR31","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa2029073","volume":"384","author":"P Hillmen","year":"2021","unstructured":"Hillmen P, Szer J, Weitz I, R\u00f6th A, H\u00f6chsmann B, Panse J, Usuki K, Griffin M, Kiladjian JJ, de Castro C, Nishimori H, Tan L, Hamdani M, Deschatelets P, Francois C, Grossi F, Ajayi T, Risitano A, Peffault de Latour R (2021) Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 384(11):1028\u20131037. https:\/\/doi.org\/10.1056\/NEJMoa2029073. Erratum in: N Engl J Med 2024;390(11):1060. 10.1056\/NEJMx240003","journal-title":"N Engl J Med"},{"issue":"7","key":"5968_CR32","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1182\/bloodadvances.2023011691","volume":"8","author":"M Griffin","year":"2024","unstructured":"Griffin M, Kelly RJ, Panse JP, DeCastro C, Szer J, Horneff R, Tan L, Yeh M, Peffault de Latour R (2024) Management of acute breakthrough hemolysis with intensive pegcetacoplan dosing in patients with PNH. Blood Adv 8(7):1776\u20131786. https:\/\/doi.org\/10.1182\/bloodadvances.2023011691","journal-title":"Blood Adv"},{"issue":"11","key":"5968_CR33","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa2308695","volume":"390","author":"R Peffault de Latour","year":"2024","unstructured":"Peffault de Latour R, R\u00f6th A, Kulasekararaj AG, Han B, Scheinberg P, Maciejewski JP, Ueda Y, de Castro CM, Di Bona E, Fu R, Zhang L, Griffin M, Langemeijer SMC, Panse J, Schrezenmeier H, Barcellini W, Mauad VAQ, Schafhausen P, Tavitian S, Beggiato E, Chew LP, Gaya A, Huang WH, Jang JH, Kitawaki T, Kutlar A, Notaro R, Pullarkat V, Schubert J, Terriou L, Uchiyama M, Wong Lee Lee L, Yap ES, Sicre de Fontbrune F, Marano L, Alashkar F, Gandhi S, Trikha R, Yang C, Liu H, Kelly RJ, H\u00f6chsmann B, Kerloeguen C, Banerjee P, Levitch R, Kumar R, Wang Z, Thorburn C, Maitra S, Li S, Verles A, Dahlke M, Risitano AM (2024) Oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria. N Engl J Med 390(11):994\u20131008. https:\/\/doi.org\/10.1056\/NEJMoa2308695","journal-title":"N Engl J Med"},{"issue":"12","key":"5968_CR34","doi-asserted-by":"publisher","first-page":"e955","DOI":"10.1016\/S2352-3026(23)00315-0","volume":"10","author":"JW Lee","year":"2023","unstructured":"Lee JW, Griffin M, Kim JS, Lee Lee LW, Piatek C, Nishimura JI, Carrillo Infante C, Jain D, Liu P, Filippov G, Sicre de Fontbrune F, Risitano A, Kulasekararaj AG, ALXN2040-PNH-301 Investigators (2023) Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial. Lancet Haematol 10(12):e955\u2013e965. https:\/\/doi.org\/10.1016\/S2352-3026(23)00315-0","journal-title":"Lancet Haematol"},{"issue":"15","key":"5968_CR35","doi-asserted-by":"publisher","first-page":"4450","DOI":"10.1182\/bloodadvances.2022006960","volume":"6","author":"JH Jang","year":"2022","unstructured":"Jang JH, Wong L, Ko BS, Yoon SS, Li K, Baltcheva I, Nidamarthy PK, Chawla R, Junge G, Yap ES (2022) Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study. Blood Adv 6(15):4450\u20134460. https:\/\/doi.org\/10.1182\/bloodadvances.2022006960","journal-title":"Blood Adv"},{"issue":"3","key":"5968_CR36","first-page":"171","volume":"42","author":"RA G\u00f3ngora-Biachi","year":"1997","unstructured":"G\u00f3ngora-Biachi RA, Gonz\u00e1lez-Mart\u00ednez P, Sosa-Mu\u00f1oz J, Castro-Sansores C, Delgado-Lamas JL, V\u00e1zquez-Villegas V, Rico-Balzadua G, Herrera-S\u00e1nchez P, Selva-Pallares J, Gonz\u00e1lez-Llaven J (1997) Historia natural de la hemoglobinuria parox\u00edstica nocturna en adolescentes, adultos y en la edad pedi\u00e1trica: la experiencia mexicana [Natural history of paroxysmal nocturnal hemoglobinuria in adolescents, adults, and children: the Mexican experience]. Sangre (Barc) 42(3):171\u2013177 Article in Spanish","journal-title":"Sangre (Barc)"},{"issue":"6","key":"5968_CR37","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1590\/s0100-879x2001000600010","volume":"34","author":"R Franco De Carvalho","year":"2001","unstructured":"Franco De Carvalho R, Arruda VR, Saad ST, Costa FF (2001) Detection of somatic mutations of the PIG-A gene in Brazilian patients with paroxysmal nocturnal hemoglobinuria. Braz J Med Biol Res 34(6):763\u2013766. https:\/\/doi.org\/10.1590\/s0100-879x2001000600010","journal-title":"Braz J Med Biol Res"},{"issue":"1","key":"5968_CR38","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1160\/TH04-06-0391","volume":"93","author":"DJ Araten","year":"2005","unstructured":"Araten DJ, Thaler HT, Luzzatto L (2005) High incidence of thrombosis in African-American and Latin-American patients with paroxysmal nocturnal haemoglobinuria. Thromb Haemost 93(1):88\u201391. https:\/\/doi.org\/10.1160\/TH04-06-0391","journal-title":"Thromb Haemost"},{"issue":"1","key":"5968_CR39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.5581\/1516-8484.20110012","volume":"33","author":"LC de Brito Junior","year":"2011","unstructured":"de Brito Junior LC, Cardoso Mdo S, Rocha EG, Anijar H, Cunha M, Saraiva JC (2011) Frequency of paroxysmal nocturnal hemoglobinuria in patients attended in Bel\u00e9m, Par\u00e1, Brazil. Rev Bras Hematol Hemoter 33(1):35\u201337. https:\/\/doi.org\/10.5581\/1516-8484.20110012. Erratum in: Rev Bras Hematol Hemoter 2011;33(2):167","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"1","key":"5968_CR40","first-page":"12","volume":"66","author":"J Hern\u00e1ndez-Reyes","year":"2014","unstructured":"Hern\u00e1ndez-Reyes J, Gonz\u00e1lez-Ram\u00edrez MP, Martag\u00f3n-Herrera N\u00c1, Rosales-Dur\u00f3n AD, Ruiz-Delgado GJ, Ruiz-Arg\u00fcelles GJ (2014) Paroxysmal nocturnal hemoglobinuria in M\u00e9xico: a 30-year, single institution experience. Rev Invest Clin 66(1):12\u201316","journal-title":"Rev Invest Clin"},{"issue":"2","key":"5968_CR41","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.bjhh.2015.01.001","volume":"37","author":"AP de Azambuja","year":"2015","unstructured":"de Azambuja AP, Malvezzi M, Bitencourt MA, Oliveira MM, Medeiros LA, Pasquini R (2015) Paroxysmal nocturnal hemoglobinuria clone in 103 Brazilian patients: diagnosis and classification. Rev Bras Hematol Hemoter 37(2):90\u201397. https:\/\/doi.org\/10.1016\/j.bjhh.2015.01.001","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"5","key":"5968_CR42","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1179\/1607845414Y.0000000195","volume":"20","author":"A Schcolnik-Cabrera","year":"2015","unstructured":"Schcolnik-Cabrera A, Labastida-Mercado N, Galindo-Becerra LS, Gomez-Almaguer D, Herrera-Rojas MA, Ruiz-Delgado GJ, Ruiz-Arguelles GJ (2015) Reduced-intensity stem cell allografting for PNH patients in the eculizumab era: The Mexican experience. Hematology 20(5):263\u2013266. https:\/\/doi.org\/10.1179\/1607845414Y.0000000195","journal-title":"Hematology"},{"issue":"6","key":"5968_CR43","first-page":"350","volume":"67","author":"AA Scherling-Ocampo","year":"2015","unstructured":"Scherling-Ocampo AA, Vargas-Ru\u00edz \u00c1G, L\u00f3pez-Karpovitch X (2015) Study of anticoagulant, procoagulant, and fibrinolytic pathways in Mexican patients with paroxysmal nocturnal hemoglobinuria. Rev Invest Clin 67(6):350\u2013356","journal-title":"Rev Invest Clin"},{"issue":"5","key":"5968_CR44","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/cyto.b.21480","volume":"92","author":"M Morado","year":"2017","unstructured":"Morado M, Freire Sandes A, Colado E, Subir\u00e1 D, Isusi P, Soledad Noya M, Bel\u00e9n Vidriales M, Sempere A, \u00c1ngel D\u00edaz J, Minguela A, \u00c1lvarez B, Serrano C, Caballero T, Rey M, P\u00e9rez Corral A, Cristina Fern\u00e1ndez Jim\u00e9nez M, Magro E, Lemes A, Benavente C, Ba\u00f1as H, Merino J, Castejon C, Gutierrez O, Rabasa P, Vescosi Gon\u00e7alves M, Perez-Andres M, Orfao A, PNH working group of the Iberian Society of Cytometry (SIC) (2017) Diagnostic screening of paroxysmal nocturnal hemoglobinuria: Prospective multicentric evaluation of the current medical indications. Cytometry B Clin Cytom 92(5):361\u2013370. https:\/\/doi.org\/10.1002\/cyto.b.21480","journal-title":"Cytometry B Clin Cytom"},{"issue":"36","key":"5968_CR45","doi-asserted-by":"publisher","first-page":"e12155","DOI":"10.1097\/MD.0000000000012155","volume":"97","author":"JMC Bastos","year":"2018","unstructured":"Bastos JMC, Pinheiro PL, Rocha LC, Bicalho EC, Cazeli AB, Marcondes SS, Pinasco GC (2018) Therapeutic challenges in pregnant women with paroxysmal nocturnal hemoglobinuria: A case report. Medicine (Baltimore) 97(36):e12155. https:\/\/doi.org\/10.1097\/MD.0000000000012155","journal-title":"Medicine (Baltimore)"},{"key":"5968_CR46","doi-asserted-by":"publisher","first-page":"102605","DOI":"10.1016\/j.bcmd.2021.102605","volume":"92","author":"AP de Azambuja","year":"2021","unstructured":"de Azambuja AP, Oliveira MM, Bitencourt MA, Bonfim C, Malvezzi M, Pasquini R (2021) Analysis of baseline characteristics, disease burden and long-term follow-up of 167 patients with paroxysmal nocturnal hemoglobinuria at a single center in Brazil. Blood Cells Mol Dis 92:102605. https:\/\/doi.org\/10.1016\/j.bcmd.2021.102605","journal-title":"Blood Cells Mol Dis"},{"issue":"3","key":"5968_CR47","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.htct.2020.06.006","volume":"43","author":"RD Can\u00e7ado","year":"2021","unstructured":"Can\u00e7ado RD, Ara\u00fajo ADS, Sandes AF, Arrais C, Lobo CLC, Figueiredo MS, Gualandro SFM, Saad STO, Costa FF (2021) Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria. Hematol Transfus Cell Ther 43(3):341\u2013348. https:\/\/doi.org\/10.1016\/j.htct.2020.06.006","journal-title":"Hematol Transfus Cell Ther"},{"issue":"5","key":"5968_CR48","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00277-022-04797-9","volume":"101","author":"BGP Pires da Silva","year":"2022","unstructured":"Pires da Silva BGP, Fonseca NP, Catto LFB, Pereira GC, Calado RT (2022) The spectrum of paroxysmal nocturnal hemoglobinuria clinical presentation in a Brazilian single referral center. Ann Hematol 101(5):999\u20131007. https:\/\/doi.org\/10.1007\/s00277-022-04797-9","journal-title":"Ann Hematol"},{"issue":"7","key":"5968_CR49","doi-asserted-by":"publisher","first-page":"e0288708","DOI":"10.1371\/journal.pone.0288708","volume":"18","author":"SF Menosi Gualandro","year":"2023","unstructured":"Menosi Gualandro SF, Salvino MA, de Oliveira B, Alves L, Jeh\u00e1 T (2023) Characteristics of paroxysmal nocturnal hemoglobinuria patients in Brazil: A retrospective administrative claims database analysis of PNH patients in Brazilian public healthcare system. PLoS One 18(7):e0288708. https:\/\/doi.org\/10.1371\/journal.pone.0288708","journal-title":"PLoS One"},{"issue":"Suppl. 1","key":"5968_CR50","first-page":"582","volume":"97","author":"M De Oliveira","year":"2012","unstructured":"De Oliveira M (2012) PNH clonal expansion following stem cell transplantation for severe aplastic anemia: A retrospective analysis in a Brazilian hospital. Haematologica 97(Suppl. 1):582","journal-title":"Haematologica"},{"issue":"Suppl. 1","key":"5968_CR51","first-page":"704","volume":"97","author":"A Garcia Carvalho","year":"2012","unstructured":"Garcia Carvalho A, Ghidetti Mangas Catarino D, Xavier Carneiro T, Blumm Ferreira F, Gil Rizzatti E, Arruda M, Oliveira Barros M, Yamamoto M, Figueiredo M, Arrais Rodrigues C (2012) Clinical and laboratory features of 26 patients with paroxysmal nocturnal hemoglobinuria in Sao Paulo-Brazil. Haematologica 97(Suppl. 1):704","journal-title":"Haematologica"},{"issue":"Suppl. 1","key":"5968_CR52","first-page":"681","volume":"97","author":"D Ghidetti Mangas Catarino","year":"2012","unstructured":"Ghidetti Mangas Catarino D, Carvalho A, Xavier Carneiro T, Blumm Ferreira F, Rizzatti E, Arruda M, Oliveira Barros M, Yamamoto M, Figueiredo M, Arrais Rodrigues C (2012) Clinical features and outcome of 16 patients with PNH treated with eculizumab in Sao Paulo-Brazil. Haematologica 97(Suppl. 1):681","journal-title":"Haematologica"},{"issue":"21","key":"5968_CR53","doi-asserted-by":"publisher","first-page":"4869","DOI":"10.1182\/blood.V122.21.4869.4869","volume":"122","author":"M Londono","year":"2013","unstructured":"Londono M, Arenas-Mantilla M, Henao-Uribe AM, Novoa R, Naranjo A, Bedon F (2013) Characteristics of paroxysmal nocturnal hemoglobinuria clones in Colombian patients. Blood 122(21):4869. https:\/\/doi.org\/10.1182\/blood.V122.21.4869.4869","journal-title":"Blood"},{"issue":"23","key":"5968_CR54","doi-asserted-by":"publisher","first-page":"4788","DOI":"10.1182\/blood.V126.23.4788.4788","volume":"126","author":"AL Brodsky","year":"2015","unstructured":"Brodsky AL, Touliet VS, Rocaspana A, Aldunate X, Alzueta AE, Barraza T, Beguelin R, Campregher G, Colin LB, Dinardo P, Gotta D, Oliveira N, Parodi C, Perinotto G, Ramirez M, Rigada G, Ronzzetti R, Rosenfeld E, Rossi B, Stivel M, Zirone S (2015) Eculizumab treatment of paroxysmal nocturnal hemoglobinuria (PNH) The Argentinian experience. Blood 126(23):4788. https:\/\/doi.org\/10.1182\/blood.V126.23.4788.4788","journal-title":"Blood"},{"issue":"Suppl. 1","key":"5968_CR55","doi-asserted-by":"publisher","first-page":"a399","DOI":"10.1093\/ndt\/gfz103.SP111","volume":"34","author":"E De Francesco Daher","year":"2019","unstructured":"De Francesco Daher E, Zu\u00f1iga JD, Marinho, Correia Pequeno G, Cavalcante Meneses G, Ferreira Silva H, Bandeira Lima D, Costa Martins AM, Bezerra da Silva G Jr (2019) Novel biomarkers of subclinical kidney injury among patients with paroxysmal nocturnal hemoglobinuria. Nephrol Dial Transplant 34(Suppl. 1):a399. https:\/\/doi.org\/10.1093\/ndt\/gfz103.SP111","journal-title":"Nephrol Dial Transplant"},{"issue":"Supplement 1","key":"5968_CR56","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1182\/blood-2019-132033","volume":"134","author":"PE Yamakawa","year":"2019","unstructured":"Yamakawa PE, Da Fonseca AR, Perez Gomes C, Mendes A, Bettoni F, Campos de Molla V, Arruda MM, Figueiredo MS, Bosco Pesquero J, Arrais-Rodrigues C (2019) PIG-a mutations in a Brazilian cohort of patients with paroxysmal nocturnal hemoglobinuria. Blood 134(Supplement 1):944. https:\/\/doi.org\/10.1182\/blood-2019-132033","journal-title":"Blood"},{"issue":"Supplement 1","key":"5968_CR57","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1182\/blood-2019-132023","volume":"134","author":"PE Yamakawa","year":"2019","unstructured":"Yamakawa PE, Da Fonseca AR, Rabelo Gomes IB, Campos de Molla V, Domingues Pereira A, Shcolnik Szor R, Arruda MM, Figueiredo MS, Arrais-Rodrigues C (2019) Clinical characteristics of Brazilian patients with paroxysmal nocturnal hemoglobinuria and changing prognosis with eculizumab. Blood 134(Supplement 1):2222. https:\/\/doi.org\/10.1182\/blood-2019-132023","journal-title":"Blood"},{"issue":"Supplement 1","key":"5968_CR58","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1182\/blood-2021-153515","volume":"138","author":"E Apodaca Chavez","year":"2021","unstructured":"Apodaca Chavez E, Rangel-Pati\u00f1o J, Juventina Tuna-Aguilar E, Garc\u00e9s-Mart\u00ednez A, Demichelis R (2021) Total oral anticoagulation for classic PNH as primary prophylaxis strategy in a complement inhibitor restricted scenario: a retrospective analysis. Blood 138(Supplement 1):1118. https:\/\/doi.org\/10.1182\/blood-2021-153515","journal-title":"Blood"},{"issue":"Supplement 1","key":"5968_CR59","doi-asserted-by":"publisher","first-page":"8656","DOI":"10.1182\/blood-2022-170818","volume":"140","author":"LG Ceja Ramirez","year":"2022","unstructured":"Ceja Ramirez LG, Vieyra AD, Alvarez J, Demichelis R, Alvarado M, Xololt M, De La Pe\u00f1a A, Perez JM, Arana L, Apodaca EI (2022) Multi-center analysis of clinical characteristics, outcomes and overall survival of an under-studied entity: paroxysmal nocturnal hemoglobinuria associated with bone marrow disorder. Blood 140(Supplement 1):8656\u20138657. https:\/\/doi.org\/10.1182\/blood-2022-170818","journal-title":"Blood"},{"issue":"10","key":"5968_CR60","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.1182\/blood-2003-01-0009","volume":"102","author":"C Hall","year":"2003","unstructured":"Hall C, Richards S, Hillmen P (2003) Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood 102(10):3587\u20133591. https:\/\/doi.org\/10.1182\/blood-2003-01-0009","journal-title":"Blood"},{"key":"5968_CR61","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/978-90-481-9485-8_22","volume":"686","author":"B Gulbis","year":"2010","unstructured":"Gulbis B, Eleftheriou A, Angastiniotis M, Ball S, Surrall\u00e9s J, Castella M, Heimpel H, Hill A, Corrons JL (2010) Epidemiology of rare anaemias in Europe. Adv Exp Med Biol 686:375\u2013396. https:\/\/doi.org\/10.1007\/978-90-481-9485-8_22","journal-title":"Adv Exp Med Biol"},{"issue":"Supplement_1","key":"5968_CR62","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1182\/blood-2019-125867","volume":"134","author":"JJ Jalbert","year":"2019","unstructured":"Jalbert JJ, Chaudhari U, Zhang H, Weyne J, Shammo JM (2019) Epidemiology of PNH and real-world treatment patterns following an incident PNH diagnosis in the US. Blood 134(Supplement_1):3407. https:\/\/doi.org\/10.1182\/blood-2019-125867","journal-title":"Blood"},{"key":"5968_CR63","doi-asserted-by":"publisher","first-page":"22","DOI":"10.11606\/s1518-8787.2020054001693","volume":"54","author":"R Caetano","year":"2020","unstructured":"Caetano R, Rodrigues PHA, Corr\u00eaa MCV, Villardi P, Osorio-de-Castro CGS (2020) The case of eculizumab: litigation and purchases by the Brazilian Ministry of Health. Rev Saude Publica 54:22. https:\/\/doi.org\/10.11606\/s1518-8787.2020054001693. Article in English, Portuguese","journal-title":"Rev Saude Publica"},{"key":"5968_CR64","unstructured":"European Medicines Agency. Soliris. Summary of Product Characteristics. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/soliris-epar-product-information_en.pdf. Accessed 12 June 2024"},{"key":"5968_CR65","unstructured":"European Medicines Agency. Ultomiris. Summary of Product Characteristics. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ultomiris-epar-product-information_en.pdf. Accessed 12 June 2024"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05968-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05968-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05968-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T19:52:14Z","timestamp":1743882734000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05968-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,5]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["5968"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05968-6","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,5]]},"assertion":[{"value":"7 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent to participate"}},{"value":"Valentina Goldschmidt has received honoraria for consulting services and academic activities from Bristol Myers Squibb; funding for conference attendance from AstraZeneca; has engaged in speaker and academic activities with Takeda. Elia Ixel Apodaca has received honoraria from AbbVie, Asofarma, AstraZeneca, and Bristol Myers Squibb. Kenny Mauricio G\u00e1lvez declares no conflicts of interest.Bruno Wannesson has received honoraria for academic lectures from AstraZeneca, Nolter, Pint Pharma, Raffo, Terumo BCT, and Therakos; and for participation in advisory boards from AstraZeneca and Pint Pharma. Phillip Scheinberg declares no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}